Chongqing fuchuang 1.1 new antitumor drug furetinib succinate capsule and its API are approved clinically
-
Last Update: 2015-10-28
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Fuxing Pharmaceutical (02196 HK) announced that its holding subsidiary Chongqing fuchuang pharmaceutical research (Chongqing fuchuang) participated in the development of furetinib succinate capsule and its API, which was approved by the clinical trial of the State Food and drug administration The new drug is jointly developed by Chongqing fuchuang and Shanghai Pharmaceutical Research Institute of Chinese Academy of Sciences, and will be jointly developed by Jiangsu Wanbang biochemical medicine, a holding subsidiary, to carry out later clinical trials; the new drug is applied for clinical application according to "chemical class 1.1" and is intended to be used for tumor treatment CDE was undertaken in March 2015 It is a special approved variety and a major special variety At present, no similar drugs with independent intellectual property rights have been listed in China According to the regulatory requirements for new drug research and development in China, a series of clinical studies on the new drug should be carried out and approved by the national drug review department before it can be put on the market.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
